Our vision is to transform the clinical care of cancer patients by developing and implementing an integrated personalised medicine approach.
We will use each individual patient’s characteristics to guide the choice of treatment, and to modify the choice of treatment as the patient’s tumour progresses and evolves.
Currently, personalised medicine is largely focused on late stage patients and based on invasive tumour biopsies.
Importantly, we will go beyond this to implement personalised medicine at diagnosis and throughout the patient journey by molecular profiling serially-sampled liquid biopsies, and matching with not only drug based therapies but also treatment with radiotherapy and surgery.
Delivery of such a vision requires comprehensive integration of basic and clinical research, a culture and strategy that has patient benefit at its heart, a broad and comprehensive platform of enabling infrastructure and technologies and people with the optimum balance of skills, interests and experience. This philosophy has guided our development over the last few years, resulting in a proven track-record of working and investing together as a successful partnership, and a globally-competitive platform for further development.